NCT06650852 - A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions

Chronic Hepatitis B Virus (HBV) Infection

Interventions

BIOLOGICAL

BRII-179

BRII-179 will be given via intramuscular injection

DRUG

BRII-835 (VIR-2218)

BRII-835 will be given via subcutaneous injection

BIOLOGICAL

PEG-IFNα

PEG-IFNα will be given via subcutaneous injection

DRUG

Placebo of BRII-179

Placebo of BRII-179 will be given via intramuscular injection

DRUG

Placebo of BRII-835

Placebo of BRII-835 will be given via subcutaneous injection

Trial Locations (14)

100000

RECRUITING

Investigative Site 86001, Beijing

RECRUITING

Investigative Site 86003, Beijing

RECRUITING

Investigative Site 86004, Beijing

RECRUITING

Investigative Site 86005, Beijing

RECRUITING

Investigative Site 86016, Beijing

200000

RECRUITING

Investigative Site 86006, Shanghai

RECRUITING

Investigative Site 86007, Shanghai

310000

RECRUITING

Investigative Site 86009, Hangzhou

510000

RECRUITING

Investigative Site 86002, Guangzhou

RECRUITING

Investigative Site 86013, Guangzhou

518000

RECRUITING

Investigative Site 86015, Shenzhen

610000

RECRUITING

Investigative Site 86010, Chengdu

RECRUITING

Investigative Site 86011, Chengdu

RECRUITING

Investigative Site 86012, Chengdu